Amsurg Corp. (NASDAQ:AMSG) shares were down 3.5% during mid-day trading on Wednesday . The stock traded as low as $61.20 and last traded at $61.99, with a volume of 1,043,807 shares. The stock had previously closed at $64.25.

Several research analysts have issued reports on AMSG shares. Cantor Fitzgerald restated a “buy” rating and issued a $95.00 price target on shares of Amsurg Corp. in a research report on Thursday, July 14th. Zacks Investment Research upgraded shares of Amsurg Corp. from a “hold” rating to a “buy” rating and set a $88.00 price target on the stock in a research report on Monday, July 11th. Jefferies Group restated a “buy” rating on shares of Amsurg Corp. in a research report on Sunday, July 3rd. Mizuho lifted their price target on shares of Amsurg Corp. from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, June 24th. Finally, Goldman Sachs Group Inc. restated a “buy” rating on shares of Amsurg Corp. in a research report on Friday, June 17th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Amsurg Corp. has an average rating of “Buy” and an average price target of $93.91.

The company’s 50-day moving average is $74.57 and its 200-day moving average is $74.39. The company has a market cap of $3.36 billion and a price-to-earnings ratio of 18.58.

Amsurg Corp. (NASDAQ:AMSG) last announced its earnings results on Tuesday, August 2nd. The company reported $1.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.02. The company had revenue of $758.50 million for the quarter, compared to analyst estimates of $769.88 million. Amsurg Corp.’s revenue for the quarter was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.97 earnings per share. On average, equities analysts predict that Amsurg Corp. will post $4.33 earnings per share for the current year.

A number of institutional investors have made changes to their positions in the stock. Redwood Investments LLC raised its position in shares of Amsurg Corp. by 20.3% in the fourth quarter. Redwood Investments LLC now owns 28,011 shares of the company’s stock valued at $2,129,000 after buying an additional 4,732 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Amsurg Corp. by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,994,029 shares of the company’s stock valued at $227,552,000 after buying an additional 92,088 shares in the last quarter. US Bancorp DE raised its position in shares of Amsurg Corp. by 30.5% in the fourth quarter. US Bancorp DE now owns 23,339 shares of the company’s stock valued at $1,774,000 after buying an additional 5,461 shares in the last quarter. Morgan Stanley raised its position in shares of Amsurg Corp. by 115.7% in the fourth quarter. Morgan Stanley now owns 182,105 shares of the company’s stock valued at $13,840,000 after buying an additional 97,682 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in shares of Amsurg Corp. by 1,872.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 194,790 shares of the company’s stock valued at $14,804,000 after buying an additional 184,912 shares in the last quarter.

AmSurg Corp. is a surgical center and physician services company. The Company is an owner and operator of ambulatory surgery centers (ASCs) in the United States. The Company is also a provider of outsourced physician services in the areas of anesthesiology, children’s services, emergency medicine and radiology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.